In Brief:
This retrospective study investigates the expression of ezrin, MMP-9, and COX-2 in 50 brachyury-verified chordoma samples by immunohistochemistry to detect possible molecular targets for future adjuvant therapy strategies. Patients' survival was correlated with immunohistochemical results, location, tumor volume, and age.